Predictive biomarker of cetuximab response incolorectal cancer patients
Posted in the Oncology Forum
#1 Feb 22, 2012
According to a recent US patent application, serum YKL-40 can be a prognostic biomarker for predicting short overall survival in patients with metastatic colorectal cancer treated with cetuximab. Details: http://www.sciclips.com/sciclips/biomarker-ne...
Add your comments below
|Lehigh Valley Children's Hospital opens final a...||Jul 20||weaponX||1|
|Can the Sunshine Vitamin Help Lymphoma Patients?||Jul 20||duh||1|
|Psychological intervention reduces fear of recu...||Jun '17||Humanspirit||1|
|Vaccine may cut HPV infections, an oral cancer ...||May '17||HPV conjob||1|
|Parker Hughes Cancer center suspending operations (Feb '08)||Apr '17||Laura||17|
|Benign tumor||Mar '17||Bharath k||1|
|Myriad Genetics Announces an Assay that Identif... (Nov '16)||Feb '17||Purplemouse2||8|
Find what you want!
Search Oncology Forum Now
Copyright © 2017 Topix LLC